Literature DB >> 8797711

Cellular immune responses to HTLV-I: immunopathogenic role in HTLV-I-associated neurologic disease.

S Jacobson1.   

Abstract

This review examines current information on cellular immune responses to the human T lymphotropic virus type I (HTLV-I). HTLV-I has been associated with a number of diseases, but this review focuses primarily on the relationship of HTLV-I with a slowly progressive neurologic disorder termed HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP). In particular, this review discusses the role of cellular immune responses to HTLV-I in patients with HAM/TSP and how these responses may be associated with the pathogenesis of this disorder. While a number of immunologic responses have been shown to be abnormal in HAM/TSP patients, studies on HTLV-I-specific cytotoxic T-cell responses (cytotoxic T lymphocytes) are specifically examined. By defining such antigen-specific functional cellular host responses to HTLV-I, we hope to understand better the underlying mechanisms that may be involved in the neuropathology of HTLV-I-associated neurologic disease. This has led to a number of HTLV-I-associated immuno-pathogenic models that may be operative in HAM/TSP patients. Importantly, based on these models, potential immunotherapeutic strategies for disease intervention can be devised. Moreover, such an analysis may have significant implications for our understanding of other HTLV-I-associated clinical disorders.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8797711     DOI: 10.1097/00042560-199600001-00017

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr Hum Retrovirol        ISSN: 1077-9450


  7 in total

1.  Selected cytotoxic T lymphocytes with high specificity for HTLV-I in cerebrospinal fluid from a HAM/TSP patient.

Authors:  Ryuji Kubota; Samantha S Soldan; Roland Martin; Steven Jacobson
Journal:  J Neurovirol       Date:  2002-02       Impact factor: 2.643

2.  Modulation of dendritic cell maturation and function by the Tax protein of human T cell leukemia virus type 1.

Authors:  Pooja Jain; Jaya Ahuja; Zafar K Khan; Saori Shimizu; Olimpia Meucci; Stephen R Jennings; Brian Wigdahl
Journal:  J Leukoc Biol       Date:  2007-04-18       Impact factor: 4.962

3.  Intrahost variations in the envelope receptor-binding domain (RBD) of HTLV-1 and STLV-1 primary isolates.

Authors:  Felix J Kim; Madakasira Lavanya; Antoine Gessain; Sandra Gallego; Jean-Luc Battini; Marc Sitbon; Valérie Courgnaud
Journal:  Retrovirology       Date:  2006-05-25       Impact factor: 4.602

4.  Comprehensive Analysis of TCR-β Repertoire in Patients with Neurological Immune-mediated Disorders.

Authors:  Alessandra de Paula Alves Sousa; Kory R Johnson; Joan Ohayon; Jun Zhu; Paolo A Muraro; Steven Jacobson
Journal:  Sci Rep       Date:  2019-01-23       Impact factor: 4.379

5.  Exacerbated inflammatory cellular immune response characteristics of HAM/TSP is observed in a large proportion of HTLV-I asymptomatic carriers.

Authors:  Silvane Braga Santos; Aurélia Fonseca Porto; André Luiz Muniz; Amélia Ribeiro de Jesus; Elza Magalhães; Ailton Melo; Walderez O Dutra; Kenneth J Gollob; Edgar M Carvalho
Journal:  BMC Infect Dis       Date:  2004-03-02       Impact factor: 3.090

Review 6.  Human T Lymphotropic Virus Type I (HTLV-I) Oncogenesis: Molecular Aspects of Virus and Host Interactions in Pathogenesis of Adult T cell Leukemia/Lymphoma (ATL).

Authors:  Sanaz Ahmadi Ghezeldasht; Abbas Shirdel; Mohammad Ali Assarehzadegan; Tahereh Hassannia; Hosian Rahimi; Rahele Miri; S A Rahim Rezaee
Journal:  Iran J Basic Med Sci       Date:  2013-03       Impact factor: 2.699

7.  Viral antigens detectable in CSF exosomes from patients with retrovirus associated neurologic disease: functional role of exosomes.

Authors:  Monique R Anderson; Michelle L Pleet; Yoshimi Enose-Akahata; James Erickson; Maria Chiara Monaco; Yao Akpamagbo; Ashley Velluci; Yuetsu Tanaka; Shila Azodi; Ben Lepene; Jennifer Jones; Fatah Kashanchi; Steven Jacobson
Journal:  Clin Transl Med       Date:  2018-08-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.